Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation
- PMID: 1657399
- DOI: 10.1016/0092-8674(91)90529-8
Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation
Abstract
Human papillomavirus (HPV) types 16 and 18 appear to play a role in the development of ano-genital malignancies, whereas HPV 6 and 11 are usually associated with benign lesions. One HPV16 oncoprotein, E6, complexes with and promotes degradation of the cellular tumor suppressor p53. Here we show that E6 proteins of both oncogenic and benign HPV types associate in vitro with p53, but binding by E6 proteins of benign HPV types cannot target p53 for degradation. A C-terminal region of E6 conserved among all HPV types is important for p53 binding. However, N-terminal sequences of E6 conserved only between oncogenic HPV types are necessary to direct p53 degradation. p53 binding by E6 appears necessary but not sufficient for this activity. All E6 proteins tested showed comparable transcriptional trans-activating activity, a property that does not require the ability to bind or direct degradation of p53.
Similar articles
-
The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300.J Virol. 1999 Aug;73(8):6209-19. doi: 10.1128/JVI.73.8.6209-6219.1999. J Virol. 1999. PMID: 10400710 Free PMC article.
-
Targeted degradation of the retinoblastoma protein by human papillomavirus E7-E6 fusion proteins.EMBO J. 1992 Jul;11(7):2425-31. doi: 10.1002/j.1460-2075.1992.tb05307.x. EMBO J. 1992. PMID: 1321031 Free PMC article.
-
The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain.Oncogene. 1995 Feb 2;10(3):457-65. Oncogene. 1995. PMID: 7845670
-
The role of TP53 in Cervical carcinogenesis.Hum Mutat. 2003 Mar;21(3):307-12. doi: 10.1002/humu.10178. Hum Mutat. 2003. PMID: 12619117 Review.
-
The role of the E6-p53 interaction in the molecular pathogenesis of HPV.Oncogene. 1999 Dec 13;18(53):7690-700. doi: 10.1038/sj.onc.1202953. Oncogene. 1999. PMID: 10618709 Review.
Cited by
-
Endogenous YAP1 activation drives immediate onset of cervical carcinoma in situ in mice.Cancer Sci. 2020 Oct;111(10):3576-3587. doi: 10.1111/cas.14581. Epub 2020 Aug 21. Cancer Sci. 2020. PMID: 32716083 Free PMC article.
-
The E6 and E7 genes of human papillomavirus type 6 have weak immortalizing activity in human epithelial cells.J Virol. 1992 Apr;66(4):2125-34. doi: 10.1128/JVI.66.4.2125-2134.1992. J Virol. 1992. PMID: 1312623 Free PMC article.
-
Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens.EMBO J. 1992 Nov;11(11):3935-40. doi: 10.1002/j.1460-2075.1992.tb05487.x. EMBO J. 1992. PMID: 1327751 Free PMC article.
-
Human papillomavirus type 16 E6-specific antitumor immunity is induced by oral administration of HPV16 E6-expressing Lactobacillus casei in C57BL/6 mice.Cancer Immunol Immunother. 2010 Nov;59(11):1727-37. doi: 10.1007/s00262-010-0903-4. Epub 2010 Aug 13. Cancer Immunol Immunother. 2010. PMID: 20706715 Free PMC article.
-
Intratumoral Heterogeneity and Clonal Evolution Induced by HPV Integration.Cancer Discov. 2023 Apr 3;13(4):910-927. doi: 10.1158/2159-8290.CD-22-0900. Cancer Discov. 2023. PMID: 36715691 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous